Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets

Alexia Hulin, Alexandre Hego, Patrizio Lancellotti and Cécile Oury

Calcific Aortic Valve Disease (CAVD) is the most common heart valve disease and its incidence is expected to rise with aging population. No medical treatment so far has shown slowing progression of CAVD progression. Surgery remains to this day the only way to treat it. Effective drug therapy can only be achieved through a better insight into the pathogenic mechanisms underlying CAVD. The cellular and molecular events leading to leaflets calcification are complex. Upon endothelium cell damage, oxidized LDLs trigger a proinflammatory response disrupting healthy cross-talk between valve endothelial and interstitial cells. Therefore, valve interstitial cells transform into osteoblasts and mineralize the leaflets. Studies have investigated signaling pathways driving and connecting lipid metabolism, inflammation and osteogenesis. This review draws a summary of the recent advances and discusses their exploitation as promising therapeutic targets to treat CAVD and reduce valve replacement.

Keywords: calcific aortic valve disease, calcification, inflammation, oxidative stress, lipids, signal transduction

INTRODUCTION

Over the course of an average day, aortic valve (AoV) leaflets open and close 100,000 times allowing unidirectionality blood flow from the left ventricle to the systemic circulation. The proper function of AoV is achieved by thin leaflets composed of three distinct layers of extracellular matrix (ECM), rich in fibrillar collagen, glycosaminoglycans (GAGs) and elastin. Calcific Aortic Valve Disease (CAVD) appears first as AoV sclerosis developing into AoV stenosis (1, 2). Macroscopically, leaflets are thickened and progressively calcified resulting into stiff leaflets with restricted movement. CAVD is one of the most common heart valve disease and its prevalence increases with aging (3). Nowadays, in western countries, 2.8% of the general population aged over 75 years is affected with moderate to severe aortic stenosis (3, 4). With life expectancy increasing, prevalence of heart valve disease is expecting to rise. Nevertheless, due to a lack of drug treatment (5), surgery remains the only way to treat it through surgical valve replacement or transcatheter aortic valve implantation.

The seeking of therapeutic targets relies on mechanistic understanding of CAVD. Due to its association with aging, CAVD used to be considered as a passive disease, but is now established that CAVD is an active cellular-driven regulated process (6). Heart valve homeostasis is tightly controlled by valve interstitial cells (VICs) embedded in ECM, valve endothelial cells (VECs) covering the leaflet, and circulating and resident immune cells. When CAVD develops, lipid deposition, inflammation and angiogenesis occur while VICs are entering an osteogenic program as a response to exposure to risk factors including age, congenital heart defect, male gender, tobacco use, diabetes, hypertension, obesity and dyslipidemia (7–9). As a result, homeostasis is disrupted,
ECM is remodeled, and formation of calcium nodules occurs. Although mechanisms leading to CAVD are still unclear, studies on diseased human aortic valves and animal models of CAVD, reviewed by Sider et al. (10), have provided valuable insights into cellular components and signaling pathways involved in the pathogenesis. This review will summarize the current findings with emphasis on valuable therapeutic candidates.

CAVD: Multi-Step Process with Endothelium Damage as Starting Point

Endothelium dysfunction is an early feature of CAVD (11, 12) and likely the result of altered blood shear stress (13). There is indeed a spatial correlation between the calcific lesions, located almost exclusively on the aortic side of AoV leaflet, and the local hemodynamic environment (14–16). The hypothesis of hemodynamic onset is reinforced by the predisposition and accelerated progression of CAVD in patients with bicuspid aortic valve (17) that display different blood flow patterns than observed with tricuspid AoV (18, 19). Endothelium damage favors lipid deposit followed by infiltration of inflammatory cells, two hallmarks of early AoV lesions (20). Therefore, lipids and cytokines will influence neighboring VECs and VICs to promote activation of VICs, ECM remodeling and mineralization of AoV leaflets (Figure 1).

Oxidized LDLs Mediate Inflammation and Mineralization

The importance of dyslipidemia in CAVD was confirmed by prevalence of CAVD in familial hypercholesterolemia caused by mutation of LDL receptor (Ldlr) and leading to abnormal circulating level of LDL (21–23). Hypercholesterolemia induced in animal models by genetic mutation (Ldlr−/−, ApoE−/−,
ApoB^{100/100} and/or combined with enriched diet further indicate that increased lipid deposits precede the emergence of inflammatory and calcification processes (21, 24). Due to association between lipid and CAVD, clinical trial using lipid level lowering drug have been carried out, but it has shown negative results in regard with reducing CAVD (5, 25–27). One of the reasons might be that statins are ineffective to reduce Lp(a) level (28, 29). Lp(a) consists of low density lipoprotein (LDL)-like particle in which apoliprotein(a) is covalently linked to apolipoprotein B100 (30). Histopathologic studies demonstrated accumulation of apolipoproteins and lipid in early stages of CAVD (31). Genome wide association study further described a SNP in LPA gene that was strongly associated with CAVD. Individuals with that SNP had higher Lp(a) plasma level and higher risk of aortic valve stenosis (32–34).

Altogether, Lp(a) appears genuinely to mediate the onset of CAVD. Deciphering the pathogenic mechanisms linking Lp(a) to CAVD has been recently acknowledged as a priority (35). Several studies highlighted a link between lipid metabolism and calcification through oxidation of LDLs. Lp(a) is a carrier of oxidized phospholipids (OxPLs), used by Lp(a)-associated phospholipase A2 (Lp-PLA2) to generate lysophosphatidylcholine (LPC), all highly expressed in human CAVD (36, 37). LPC is then transformed into lysophosphatidic acid (LPA) by ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2), secreted by stimulated VICs (38). LPA is also produced during non-oxidative transformation of LDLs. Therefore, LPA activates VICs through enzymatic LPAR1/RhoA/NF-κb signaling, and mediates mineralization through BMP2 expression (38, 39). The requirement for RhoA to promote calcific nodule was also illustrated in vitro (40). The signaling pathway is confirmed with decreased AoV mineralization when using Ki16425, an inhibitor of LPAR1, in Ldlr^{−/−}, ApoB^{100/100} mice fed with high fat and high sucrose diet (39). It is important to mention that changes in the ECM, with accumulation of glycosaminoglycans, precede and favor oxLDL retention (24, 41, 42).

The findings indicate that lowering Lp(a), OxLDL or targeting LPAR1 are attractive options and might be used to prevent the onset of CAVD. Multiple treatment options are currently suggested to decrease Lp(a). IONIS-APO(a)Rx and IONIS-APO(a)-LpRx, antisense oligonucleotide targeting Apo(a) mRNA have been shown to lower Lp(a) level (43). Targeting Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), a hepatic protease that promotes LDLR destruction, might be a way to decrease LDL and oxidative products. This might be achieved with monoclonal antibodies, Alirocumab and Evolocumab (44), or by using Inclisiran, a small RNAi targeting PCSK9 (45, 46).

**Inflammation Contributes to Calcification**

Inflammation occurs after endothelium activation and lipid deposition. Microarray analysis of human CAVD (47) and Rapacz familial hypercholesterolemia swine, an established model of human FH (21) shows upregulation of inflammation-related genes and chemokines. Histological studies present inflammatory cells, composed of macrophages, B and T cells found near osteoblast-like cells and calcified area in human CAVD (20, 48, 49). PET imaging using 18-Fluorodeoxyglucose uptake (18F-FDG) to monitor inflammation reports higher 18F-FDG uptake in patients with AoV sclerosis and stenosis and a raise of the activity as the disease gets more severe (50).

Besides activation of endothelial cells (11, 12), OxLDLs trigger proinflammatory cytokines expression and promotes infiltration of immune cells into AoV leaflets (42, 51, 52). In diseased AoV, higher oxLDL content correlates with higher amounts of inflammatory cells (53). During inflammation, immune cells secrete inflammatory cytokines including IL-2 (54), IL-1β (55), TNF-α (56, 57), IL6(58) and MMPs (55, 59) than stimulates VICs, ECM remodeling and promote the expression of genes involved in osteogenesis (52). Altogether, data support that CAVD is an inflammatory disease, and inflammation may drive calcification.

Although inflammation precedes ECM remodeling and calcification, inflammation over the course of the disease has not been fully explored yet. Similarly, immune cells display a broad heterogeneity with specific function. Thorough characterization of macrophages, T cells or B cells is now just starting to be done in the context of CAVD. M1 macrophage subset have recently been found to be the predominant macrophage subset in CAVD, promoting osteogenic differentiation of VICs through TNF-α and IL-6 secretion (58, 60). T cells are also reported surrounding calcified area. T cells favor calcification through cytokine TNF-α and TNFSF11 expression (56, 61, 62). Increased T cells in diseased AoV is likely the result of increased circulating CD8 + T cells (63). Activated T cells infiltrate the leaflets and surround calcified area and display high level of inflammatory cytokine IFN-γ (62). Although TNFSF11 promotes osteoclast activity, aberrant IFN-γ level impairs calcium resorption by valve osteoclast. Therefore, calcium accumulates in the leaflets and facilitates nodule formations (62). A similar study indicates that macrophages surrounding calcium deposits in human atherosclerotic are defective and unable to resorb calcification (64). Such role of macrophage in CAVD have not been explored yet. Circulating Tregs are also measured in patients with CAVD and associate with disease progression (65). Although dendritic cells are found abundantly in heart valve and accumulate in AoV stenosis, their contribution to CAVD is still unknown (51, 66). Deeper understanding of regulation, timing and functional role of immune cells in CAVD will bring valuable information to determine how targeting inflammation might help preventing pathogenesis.

**VECs Are Natural Inhibitors of Calcification, Through NO Release, but Activators Through Oxidative Stress**

Inflammatory cytokines, TNF-α and IL-6, induce valve endothelial-to-mesenchymal (EMT) transformation through Akt/NF-kb signaling and reduce endothelial nitric-oxide synthase (eNOS) expression (67). Although some markers of EMT are measured in human calcified aortic valves (67), studies have still to address if EMT contribute to pathogenesis of CAVD. VECs have the particularity to display side-specific heterogeneity. Endothelium on the aortic side displays an antioxidative and
anti-inflammatory phenotype defined by its RNA expression profile (15). Thus, aortic side of AoV demonstrates protection against repetitive insult in normal AoV. As consequence, VECs are releasing nitric-oxide (NO), a natural inhibitor of pathogenic differentiation of VICs into myofibroblast and osteooblasts (68). Increased NO release has been shown to inhibit calcific nodule formation in vitro (69) and in vivo with atorvastatin treatment (70). On the opposite, in CAVD, altered mechanical stimulus, oxLDLs or TNF-α impair eNOS expression (68, 71, 72). Concomitantly, uncoupling of NO synthase leads to increased production of superoxide and oxidative stress which drives calcification (73). The critical role of endothelium and eNOS was further illustrated through modulation of a multifunctional enzyme dipeptidyl peptidase-4 (DPP4) and insulin growth factor-1 (IGF-1). Upon NO depletion, DPP4 increases in human VICs and limits IGF-1 signaling leading to enhanced calcification. Treatment of rabbit and mouse model of CAVD with Sitagliptin, a selective DPP4 inhibitor, was protective against AoV calcification (74). Similarly, the protective role of VECs is illustrated by TGF-β1 expression that translocates Sox9 into VICs nucleus and prevent calcific nodule formation (75, 76). Therefore, enhancing protective role of VECs, during early phase of disease, must be exploited. Notably, increasing NO production with statins or using DPP4 inhibitor, broadly used as hypoglycemic drugs for treatment of type 2 diabetes mellitus, might mitigate CAVD.

VICs Differentiate Into Osteoblast-Like Cells and Mineralize the Leaflets

Histological studies report the formation of bone nodules in stenotic CAVD resulting from deposition of calcium in the form of hydroxypatite in the valve leaflet (49). Once heart valve development is complete, VICs become quiescent, but in disease get activated and turn into active phenotype. In response to pathological stimuli, VICs differentiate into osteoblast-like cells with abnormal expression of typical bone genes, including Runx2, Alkaline Phosphatase (ALP), Osteopontin (SPP1), BMP2, and with abnormal expression of typical bone genes, including Runx2, Alkaline Phosphatase (ALP), Osteopontin (SPP1), Runx2, with abnormal expression of typical bone genes, including Runx2, Alkaline Phosphatase (ALP), Osteopontin (SPP1), Runx2, including Runx2, Alkaline Phosphatase (ALP), Osteopontin (SPP1), Osteocalcin (BGLAP) (47) resulting in calcified ECM. Apart from promoting inflammation, OxLDLs and Lp(a) can also directly activate VICs through LPAR1 (38, 39) and TLR activation (52, 77–79), This interaction contributes to trigger GAG accumulation, in a positive feedback loop, and upregulates osteogenic enzyme gene expression through BMP2 and IL6 expression (38, 42, 80).

Different molecular mechanisms are involved in VICs osteogenic differentiation and shared with bone formation (81, 82). Stimulation of VICs culture with OxLDLs and hypercholesterolemia animal model have been used to investigate signaling pathway underlying osteogenic differentiation. Also studies in klotho null mice have been useful to investigate AoV calcification with minimal inflammation (83). BMP2, along with osteogenic gene expression, are the usual markers measured to assess VICs osteogenic differentiation. BMP signaling is increased in human CAVD illustrated by increased BMP2, BMP4 ligands and phosphorylation of Smad1/5/8 (82, 84, 85). Downregulation of Smad6, an inhibitor of BMP signaling, enhance BMP signaling (84, 86). Inhibition of osteogenic gene expression and calcific nodule formation by targeting Alk3, BMP receptor type-1A, strongly indicate that LDN-193189, a small molecule inhibitor of BMP signaling, should be used to prevent calcification in late stage of CAVD (85).

Mutation in Notch1 and its association with BAV and AoV calcification highlighted the role of Notch signaling in CAVD (87). Later, studies confirms that Notch signaling represses osteogenic gene expression (88, 89) and is regulated by NO released by endothelial cells (90). Decreased Notch signaling is not just observed in patients with mutated Notch1 but also in patients with idiopathic CAVD where increased long non-coding RNA H19, resulting from hypomethylation, prevents Notch1 expression (91). The role of prostaglandins has been illustrated in osteogenesis (92, 93), but only recently in CAVD. Prostaglandins are synthesized by COX2, an enzyme highly expressed by VICs in CAVD (94). Pharmacological inhibition of COX2 activity with Celecoxib, a nonsteroidal anti-inflammatory (NSAID) drugs, is sufficient to reduces AoV calcification in Klotho null mice (94). Celecoxib is clinically used to treat joint and/or muscle pain (95) but was associated with increased cardiovascular risk (96). Cardiovascular safety of celecoxib is nowadays controversial (97) as recent report indicate that cardiovascular risk associated with moderate doses of celecoxib is not greater than associated with non-selective-NSAID ibuprofen (98). Additional research must evaluate the effectiveness of COX2 inhibitor in human CAVD.

Non-canonical Wnt5b and Wnt11 ligands are found elevated in macrophages of human calcified AoV. Moreover, the ligands stimulate VICs, apoptosis and calcium deposits (99). Abundant expression of Fzd receptors and co-receptors Lrp5/6 also suggest the involvement of canonical Wnt/β-catenin signaling in CAVD (81, 100). In vitro, Wnt treatment of VICs inhibit chondrogenic differentiation and promote osteogenic gene expression (101, 102) while Lrp5/6 is required to promote calcification in hypercholesterolema mouse model (103). In Axin2 KO mice, increased canonical Wnt/β-catenin signaling promotes ECM remodeling and BMP signaling but fails to calcify AoV (104). The findings illustrate that Wnt signaling is required but might not be sufficient to promote end-stage calcification. These data illustrate the importance to further study the role of Wnt signaling in CAVD as specific inhibitors are being tested (105).

VIC osteogenic differentiation has been one of the most studied process in CAVD due to available cell culture model. However, VIC remains a poorly defined cell type. Heterogeneity of VIC population is underappreciated during heart valve homeostasis and disease. Being able to define which cell type is activated and/or differentiated across disease is a major goal in order to present innovative therapeutic options.

CONCLUSIONS

CAVD is a complex multi-step event that involves numerous biological processes from lipid accumulation, inflammation to osteogenesis. Understanding the underlying molecular and cellular processes is crucial in the establishment of therapeutic targets. Clinical, histological and animal model studies have allowed better characterization of the disease and show the importance of cross-talk between lipids, immune cells, VECs and VICs. As a result, putative molecular targets with available treatments (Table 1) emerge for each...
stage of CAVD. Giving the multifactorial and complex interplay, timing and combination of therapy should be considered. In the context of appropriate therapeutic timing, accurate biomarkers should be defined. Similarly, thorough knowledge of the heterogeneity and function of valve cell subtype, over the course of the disease, may provide better targeting of the "diseased" cells. Overall, recent advances and future directions bring hope for the development of efficient drug treatment and for the reduction of valve replacement surgeries.

**AUTHOR CONTRIBUTIONS**

AHu wrote the manuscript. AHe drafted the figure. PL provided intellectual contributions and edited the manuscript. CO drafted and revised the manuscript.

**FUNDING**

The authors received a grant from the European Regional Development Fund (Interreg V - Polyvalve).

**ACKNOWLEDGMENTS**

AHu is supported by an Interreg V grant. CO is Senior Research Associate at the Belgian Funds for Scientific Research (F.R.S.-FNRS, Belgium).

**REFERENCES**

1. Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. *Nat Rev Dis Primers* (2016) 2:16006. doi: 10.1038/nrdp.2016.6
2. Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, et al. Calcific aortic valve disease: a consensus summary from the alliance of investigators on calcific aortic valve disease. *Arterioscler Thromb Vasc Biol* (2014) 34(11):2387–93. doi: 10.1161/ATVBAHA.114.302523
3. Nakomo VT, Gardin JM, Skelton TN, Gott diener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. *Lancet* (2006) 368(9540):1005–11. doi: 10.1016/S0140-6736(06)69208-8
4. Benjamin EJ, Blaha MJ, Chiue SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. *Circulation* (2017) 135(10):e146–603. doi: 10.1161/CIR.0000000000004858
5. Hutchinson JD, Akikawa E, Merryman WD. Potential drug targets for calcific aortic valve disease. *Nat Rev Cardiol* (2014) 11(4):218–31. doi: 10.1038/nrrcardio.2014.1
6. Rajamannan NM, Evans FJ, Akikawa E, Grande-Allen KJ, Demer LL, Heistad DD, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group. Executive summary: Calcific aortic valve disease-2011 update. *Circulation* (2011) 124(16):1783–91. doi: 10.1161/CIRCULATIONAHA.110.006767
7. Mosch J, Gleissner CA, Body S, Akikawa E. Histopathological assessment of calcification and inflammation of calcific aortic valves from patients with and without diabetes mellitus. *Histol Histopathol* (2017) 32(3):293–306. doi: 10.14670/HH-11-797
8. Stewart BE, Sisovick D, Lind BK, Gardin JM, Gott diener JS, Smith VE, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular health study. *J Am Coll Cardiol* (1997) 29(3):630–4.
9. Testut A, Nguyen V, Mathieu T, Kerneis C, Arangalone D, Kubota N, et al. Influence of metabolic syndrome and diabetes on progression of calcific aortic valve stenosis. *Int J Cardiol* (2017) 244:248–53. doi: 10.1016/j.ijcard.2017.06.104
10. Sider KI, Blaser MC, Simmons CA. Animal models of calcific aortic valve disease. *Int J Inflamm* (2011) 2011:1–18. doi: 10.4061/2011/364310
11. Ghaisas NK, Foley JB, O’Brien DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. *J Am Coll Cardiol* (2000) 36(7):2257–62. doi: 10.1016/S0735-1097(00)00998-0
12. Poggianni E, Venneri L, Chubuchny V, Jambrik Z, Baroncini LA, Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. *J Am Coll Cardiol* (2003) 41(13):48–51. doi: 10.1016/S0735-1097(02)02622-0
13. Sucosky P, Balachandran K, Elhammali A, Jo H, Yoganathan AP. Altered shear stress stimulates upregulation of endothelial VCAM-1 and ICAM-1 in a BMP-4- and TGF-beta1-dependent pathway. *Arterioscler Thromb Vasc Biol* (2009) 29(2):234–60. doi: 10.1161/ATVBAHA.108.176347
14. Gould ST, Sriruganapalan S, Simmons CA, Anseth KS. Hemodynamic and cellular response feedback in calcific aortic valve disease. *Circ Res* (2013) 113(2):186–97. doi: 10.1161/CIRCRESAHA.112.300154
15. Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. *Circ Res* (2005) 96(7):792–9. doi: 10.1161/01.RES.0000161998.92009.6
16. Yap CH, Saikrishnan N, Yoganathan AP. Experimental measurement of dynamic fluid shear stress on the ventricular surface of the aortic valve leaflet. *Biomech Model Mechanobiol* (2012) 11(1-2):231–44. doi: 10.1007/s10237-011-0306-2
17. Roberts WC, Ko JM. Frequency by decades of unicusp, bicusp, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. *Circulation* (2005) 111(7):920–5. doi: 10.1161/01.CIR.0000156234.48048.C5
18. Meierhofer C, Schneider EP, Lyko C, Hutter A, Martinoff S, Markl M, et al. Wall shear stress and flow patterns in the ascending aorta in patients with bicuspid aortic valves differ significantly from tricuspid aortic valves: a
35. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) as a marker of cardiovascular risk in individuals with intermediate cholesterol levels: a prospective study. *Euro Heart J Cardiovasc Imaging* (2013) 14(8):797–804. doi: 10.1093/ehjci/jes273

34. Arsenault BJ, Boekholdt SM, Dubé MP, Rhéaume E, Wareham NJ, Khaw KT, et al. Apolipoprotein(a) and myocardial infarction: a meta-analysis of 35 randomized controlled trials. *J Am Coll Cardiol* (2015) 65(5):460–9. doi: 10.1016/j.jacc.2013.05.105

33. Bouchareb R, Mahmut A, Nsaibia MJ, Boulanger MC, Dahou A, Lépine JL, et al. Autotaxin-derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. *Circulation* (2015) 132(8):677–90. doi: 10.1161/CIRCULATIONAHA.115.016757

32. OtDL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2017) 113(11):1351–63. doi: 10.1093/cvr/cvx089

31. Nsaibia MJ, Boulanger MC, Bouchareb R, Mikanne G, Le Quang K, Hadji F, et al. OxDL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2015) 103(11):1522–8. doi: 10.1161/01.CIR.103.11.1522

30. Mikanne G, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow N, et al. Calcific aortic valve stenosis: hard disease in the heart. *Eur Heart J* (2014) 35(10):1313–9. doi: 10.1093/eurheartj/ehu019

29. Breslow N, Leopold B, Bolzano K, Weintraub MS, Breslow N, et al. OxDL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2017) 113(11):1351–63. doi: 10.1093/cvr/cvx089

28. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. *J Am Coll Cardiol* (2014) 63(5):460–9. doi: 10.1016/j.jacc.2013.05.105

27. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow N, et al. Calcific aortic valve stenosis: hard disease in the heart. *Eur Heart J* (2014) 35(10):1313–9. doi: 10.1093/eurheartj/ehu019

26. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. OxDL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2017) 113(11):1351–63. doi: 10.1093/cvr/cvx089

25. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic annulus: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation* (2010) 121(2):306–14. doi: 10.1161/CIRCULATIONAHA.109.900227

24. Varghese MJ. Familial hypercholesterolemia: a review. *Ann Pediatr Cardiol* (2014) 7(2):107. doi: 10.4103/0974-2069.132478

23. Ot DL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2017) 113(11):1351–63. doi: 10.1093/cvr/cvx089

22. Rajamanan NM. The role of Lrp5/6 in valve disease: experimental hypercholesterolemia in the Apoe-/-. /Lrp5/6-/- mice. *Cell Biochem* (2011a) 112(10):2987–91. doi: 10.1016/j.chb.2012

21. Porras AM, Shahmuganayagam D, Meudt JJ, Krueger CG, Hacker TA, Rahko PS, et al. Development of aortic valve disease in familial hypercholesterolemic swine: implications for elucidating disease etiology. *J Am Heart Assoc* (2015) 4(10):e002254. doi: 10.1161/JAHA.115.002254

20. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, Ot DL-/-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. *Cardiovasc Res* (2017) 113(11):1351–63. doi: 10.1093/cvr/cvx089

19. Saikrishnan N, Mirabella L, Yoganathan AP. Bicuspid aortic valves are associated with increased wall and turbulence shear stress levels compared to trileaflet aortic valves. *Biomech Model Mechanobiol* (2015) 14(3):577–88. doi: 10.1007/s10237-014-0462-3

18. Varghese MJ. Familial hypercholesterolemia: a review. *Ann Pediatr Cardiol* (2014) 7(2):107. doi: 10.4103/0974-2069.132478

17. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* (2005) 352(23):2389–97. doi: 10.1056/NEJMoa043876

16. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* (2008) 359(13):1343–56. doi: 10.1056/NEJMoa0804602

15. Varghese MJ. Familial hypercholesterolemia: a review. *Ann Pediatr Cardiol* (2014) 7(2):107. doi: 10.4103/0974-2069.132478

14. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* (2008) 359(13):1343–56. doi: 10.1056/NEJMoa0804602

13. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* (2005) 352(23):2389–97. doi: 10.1056/NEJMoa043876
proliferation in calcific aortic valve stenosis. *Atherosclerosis* (2003) 170(2):205–11. doi: 10.1016/S0021-9150(03)00284-3

56. Isoda K, Matsuji T, Kondo H, Iwakura Y, Ohsumu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice. *Arterioscler Thromb Vasc Biol* (2010) 30(4):708–15. doi: 10.1161/ATVBAHA.109.1701749

57. Kaden JJ, Kılıç R, Sarıköç A, Hagl S, Lang S, Hoffmann U, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myocardiofibroblasts: a potential regulatory mechanism of valvular calcification. *Int J Mol Med* (2015) 36(1):869–72. doi: 10.3892/ijmm.16.5.869

58. Li G, Qiao W, Zhang W, Li F, Shi J, Dong N. The shift of macrophages toward M1 phenotype promotes aortic valve calcification. *Thorac Cardiovasc Surg* (2017) 153(6):1318–27. doi: 10.1016/j.jtcs.2017.01.052

59. Edpe ME, Shirani J, Wolf P, Brown DL. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. *Cardiovasc Pathol.* (2000) 9(5):281–6. doi: 10.1016/S1054-8807(00)00043-0

60. Liu XF, Wang Y, Zheng DD, Xu HX, Wang T, Pan M, et al. M1 macrophages promote aortic valve calcification mediated by microRNA-214/TWIST1 pathway in valvular interstitial cells. *Am J Transl Res* (2016) 8(12):5773–83.

61. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarıköç A, Kılıç R, et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in nonrheumatic aortic stenosis. *Cardiovasc Pathol.* (2017) 26(6):574–80. doi: 10.1016/j.jcpath.2017.05.006

62. Lubrano V, Vassalle C, Blandizzi C, del Tacca M, Palombo C, L'Abbate A, et al. Interferon-γ released by activated CD8+ T lymphocytes impairs the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. *Arterioscler Thromb Vasc Biol* (2016) 36(2):32–38. doi: 10.1161/ATVBAHA.115.306091

63. Winchester R, Wiesendanger M, O'Brien W, Zhang HZ, Maurer MS, Gillam M307528200. Reduced SOX9 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. *J Cell Physiol* (2004) 200(3):400–6. doi: 10.1002/jcp.20031
93. Zhang X, Schwarz EM, Young DA, Puzas JE, Rosier RN, O’Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest (2002) 109(11):1405–15. doi: 10.1172/JCI0215681
94. Wirrig EE, Gomez MV, Hinton RB, Yutzey KE. COX2 inhibition reduces aortic valve calcification in vivo. Arterioscler Thromb Vasc Biol (2015) 35(4):938–47. doi: 10.1161/ATVBAHA.114.305159
95. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med (2006) 119(3):255–66. doi: 10.1016/j.amjmed.2005.09.054
96. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 352(11):1071–80. doi: 10.1056/NEJMoa050405
97. Pepine CJ, Garbel PA. Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clin Cardiol (2017) 40(12):1352–. doi: 10.1002/clc.22814
98. Nissen SE, Yeoamans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med (2016) 375(26):2519–29. doi: 10.1056/NEJMo1611593
99. Albanese I, Yu B, Al-Kindi H, Barratt B, Ott L, Al-Relai M, et al. Role of noncanonical Wnt signaling pathway in human aortic valve calcification. Arterioscler Thromb Vasc Biol (2017) 37(3):545–52. doi: 10.1161/ATVBAHA.116.308394
100. Siddiqua A, Yu B, Khan K, Buying R, Al-Kindi H, Alaws H, et al. Expression of the Frizzled receptors and their co-receptors in calcified human aortic valves. Can J Physiol Pharmacol (2018) 96(2):208–14. doi: 10.1139/cjpp-2017-0577
101. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol (2010) 338(2):127–35. doi: 10.1016/j.ydbio.2009.11.030
102. Fang M, Alfieri CM, Hulin A, Conway SJ, Yutzey KE. Loss of β-catenin promotes chondrogenic differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol (2014) 34(12):2601–8. doi: 10.1161/ATVBAHA.114.304579
103. Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory. J Cell Biochem (2011b) 112(9):2222–9. doi: 10.1002/jcb.23182
104. Hulin A, Moore V, James M, Yutzey KE. Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease. Cardiovasc Res (2017) 113(1):40–51. doi: 10.1093/cvr/cvw229
105. Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov (2014) 13(7):513–32. doi: 10.1038/nrd4233

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Hulin, Hego, Lancellotti and Oury. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.